Display options
Cite
Boon MR, Bakker LEH, Prehn C, et al. LysoPC-acyl C16:0 is associated with brown adipose tissue activity in men. Metabolomics. 2017;13(5):48doi: 10.1007/s11306-017-1185-z.
Boon, M. R., Bakker, L. E. H., Prehn, C., Adamski, J., Vosselman, M. J., Jazet, I. M., Arias-Bouda, L. M. P., van Lichtenbelt, W. D. M., van Dijk, K. W., Rensen, P. C. N., & Mook-Kanamori, D. O. (2017). LysoPC-acyl C16:0 is associated with brown adipose tissue activity in men. Metabolomics : Official journal of the Metabolomic Society, 13(5), 48. https://doi.org/10.1007/s11306-017-1185-z
Boon, Mariëtte R, et al. "LysoPC-acyl C16:0 is associated with brown adipose tissue activity in men." Metabolomics : Official journal of the Metabolomic Society vol. 13,5 (2017): 48. doi: https://doi.org/10.1007/s11306-017-1185-z
Boon MR, Bakker LEH, Prehn C, Adamski J, Vosselman MJ, Jazet IM, Arias-Bouda LMP, van Lichtenbelt WDM, van Dijk KW, Rensen PCN, Mook-Kanamori DO. LysoPC-acyl C16:0 is associated with brown adipose tissue activity in men. Metabolomics. 2017;13(5):48. doi: 10.1007/s11306-017-1185-z. Epub 2017 Mar 03. PMID: 28316560; PMCID: PMC5334436.
Copy Download .nbib Format: NLM
Share it on

Metabolomics. 2017;13(5):48. doi: 10.1007/s11306-017-1185-z. Epub 2017 Mar 03.

LysoPC-acyl C16:0 is associated with brown adipose tissue activity in men.

Metabolomics : Official journal of the Metabolomic Society

Mariëtte R Boon, Leontine E H Bakker, Cornelia Prehn, Jerzy Adamski, Maarten J Vosselman, Ingrid M Jazet, Lenka M Pereira Arias-Bouda, Wouter D Marken van Lichtenbelt, Ko Willems van Dijk, Patrick C N Rensen, Dennis O Mook-Kanamori

Affiliations

  1. Department of Medicine, Division of Endocrinology, Leiden University Medical Center, P.O. Box 9600, 2300 RC Leiden, The Netherlands.
  2. Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, The Netherlands.
  3. Department of Human Biology, NUTRIM School for Nutrition, Toxicology and Metabolism, Maastricht University Medical Center, Maastricht, The Netherlands.
  4. Institute of Experimental Genetics, Genome Analysis Center, Helmholtz Zentrum München, Neuherberg, Germany.
  5. German Center for Diabetes Research, Neuherberg, Germany.
  6. Lehrstul für Experimentelle Genetik, Technische Universität München, Freising-Weihenstephan, Germany.
  7. Department of Radiology, Division of Nuclear Medicine, Leiden University Medical Center, Leiden, The Netherlands.
  8. Department of Nuclear Medicine, Alrijne ziekenhuis, Leiderdorp, The Netherlands.
  9. Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands.
  10. Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands.

PMID: 28316560 PMCID: PMC5334436 DOI: 10.1007/s11306-017-1185-z

Abstract

INTRODUCTION: Brown adipose tissue (BAT) recently emerged as a potential therapeutic target in the treatment of obesity and associated disorders due to its fat-burning capacity. The current gold standard in assessing BAT activity is [

OBJECTIVE: We aimed to identify metabolites in serum that are associated with BAT volume and activity in men.

METHODS: We assessed 163 metabolites in fasted serum of a cohort of twenty-two healthy lean men (age 24.1 (21.7-26.6) years, BMI 22.1 (20.5-23.4) kg/m

RESULTS: After correction for multiple testing, fasting concentrations of lysophosphatidylcholine-acyl (LysoPC-acyl) C16:1, LysoPC-acyl C16:0 and phosphatidylcholine-diacyl C32:1 showed strong positive correlations with BAT volume (β= 116 (85-148) mL, R

CONCLUSIONS: LysoPC-acyl C16:0 is associated with BAT activity in men. Since BAT is regarded as a promising tool in the battle against obesity and related disorders, the identification of such a noninvasive marker is highly relevant.

Keywords: Brown adipose tissue; LysoPC-acyl C16:0; Metabolomics; [18F]FDG PET-CT scan

References

  1. J Clin Invest. 2013 Aug;123(8):3395-403 - PubMed
  2. Nat Med. 2011 Feb;17(2):200-5 - PubMed
  3. Am J Physiol Regul Integr Comp Physiol. 2014 Jul 15;307(2):R103-13 - PubMed
  4. Int J Obes (Lond). 2015 Dec;39(12 ):1696-702 - PubMed
  5. N Engl J Med. 2009 Apr 9;360(15):1500-8 - PubMed
  6. Circ Res. 2016 Jan 8;118(1):173-82 - PubMed
  7. Eur J Clin Invest. 1982 Apr;12(2):113-20 - PubMed
  8. Am J Clin Nutr. 2012 Apr;95(4):845-50 - PubMed
  9. Diabetes. 2012 Dec;61(12):3106-13 - PubMed
  10. Lancet Diabetes Endocrinol. 2014 Mar;2(3):210-7 - PubMed
  11. Physiol Rev. 2004 Jan;84(1):277-359 - PubMed
  12. Nat Commun. 2017 Apr 19;8:15010 - PubMed
  13. Metabolomics. 2013 Apr;9(2):506-514 - PubMed
  14. Nat Genet. 2010 Feb;42(2):137-41 - PubMed
  15. J Lipid Res. 1968 Mar;9(2):155-67 - PubMed
  16. J Lipid Res. 2015 Jan;56(1):51-9 - PubMed
  17. J Clin Invest. 2013 Aug;123(8):3404-8 - PubMed
  18. Diabetes. 2015 Jul;64(7):2388-97 - PubMed
  19. Klin Wochenschr. 1983 Feb 1;61(3):119-32 - PubMed
  20. Cell Metab. 2016 Aug 9;24(2):210-22 - PubMed
  21. Nat Med. 2015 Aug;21(8):863-5 - PubMed
  22. Am J Clin Nutr. 2013 Jul;98(1):57-64 - PubMed

Publication Types